Enfuvirtide (C204H301N51O64) belongs to the fusion inhibitor class of antiretrovirals. It is derived from a heptad-repeat region (HR2) of the HIV-1 transmembrane glycoprotein gp41. By mimicking this region, the peptide competitively binds to the complementary HR1 coiled-coil domain on gp41, preventing the conformational change required for virus–cell membrane fusion and thereby blocking viral entry before reverse transcription occurs.
In terms of classification, enfuvirtide sits within the broader category of biomimetic or sequence-derived therapeutic peptides , longer-chain, non-endogenous constructs designed to replicate or antagonise a naturally occurring protein–protein interaction. At 36 residues it is considerably larger than most short bioactive peptides and is administered by subcutaneous injection because, like most peptides of its size, it undergoes rapid proteolytic degradation in the gastrointestinal tract and has negligible oral bioavailability.
In Australia, enfuvirtide is a prescription-only medicine listed on the Pharmaceutical Benefits Scheme for treatment-experienced adults with evidence of HIV-1 replication despite antiretroviral therapy. It is regulated under Schedule 4 of the Poisons Standard (the Standard for the Uniform Scheduling of Medicines and Poisons). Supply outside a valid prescription pathway is unlawful under Australian law. The Therapeutic Goods Administration (TGA) maintains the approved product entry on the Australian Register of Therapeutic Goods (ARTG).
From a pharmacokinetic standpoint, subcutaneous bioavailability is approximately 84%, with peak plasma concentrations reached around four hours post-injection. Metabolism occurs via proteolytic catabolism into constituent amino acids, which are recycled through normal amino acid pathways. Half-life is roughly 3.8 hours, necessitating twice-daily dosing. These characteristics are broadly representative of the pharmacokinetic challenges faced by all large therapeutic peptides.
Sources: